VRDN

Viridian Therapeutics, Inc.

Healthcare
Biotechnology
$2.41B market cap

Forecast run · Sep 14, 2026Upside rank 1112 of 3,136

Model Signal

ForecastQ Daily Probabilities

42.9%

36.4%

19.7%

Analyst Consensus

Recommendation2.13/5 Buy

Last price$21.24

Price target$36.14

Implied move+70.2%

Analysts16

ForecastQ Portfolios

VRDN is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.